OncoMatch/Clinical Trials/NCT06900595
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Is NCT06900595 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Cabozantinib for locally advanced adrenal cortical carcinoma.
Treatment: Cabozantinib · Cemiplimab — This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV, STAGE III, STAGE IV (AJCC v8)
Locally advanced unresectable or recurrent/metastatic disease
Performance status
ECOG/LANSKY/KARNOFSKY 0–2
ECOG performance 0 - 2 (age 18 and above); Lansky scale ≥ 50 (12 to <16 years); Karnofsky scale ≥ 50 (≥16 to <18 years)
Prior therapy
Cannot have received: cMET inhibitor (cabozantinib)
No prior treatment with cabozantinib or other cMET inhibitors
Cannot have received: anti-CTLA-4 therapy
No prior treatment with anti-CTLA-4
Cannot have received: anti-PD-1 therapy
No prior treatment with anti-PD-1/PD-L1 therapy
Cannot have received: anti-PD-L1 therapy
No prior treatment with anti-PD-1/PD-L1 therapy
Lab requirements
Blood counts
ANC ≥ 1,000/mcL; Platelet count ≥ 100,000/mcL; Hemoglobin ≥ 8 g/dL
Kidney function
Random Urine Creatinine Ratio (UPCR) ≤ 1 mg/mg; Calculated creatinine clearance ≥ 30 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 mg/dL for Gilbert's); AST/ALT ≤ 3 x ULN
Cardiac function
NYHA class II or better if cardiac history; no congenital long QT syndrome; no myocarditis; no MI or unstable angina within 6 months
ANC ≥ 1,000/mcL; Platelet count ≥ 100,000/mcL; Hemoglobin ≥ 8 g/dL; Total bilirubin ≤ 1.5 x ULN (≤ 3 mg/dL for Gilbert's); AST/ALT ≤ 3 x ULN; UPCR ≤ 1 mg/mg; Creatinine clearance ≥ 30 mL/min; NYHA class II or better if cardiac history
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Lurie Children's Hospital-Chicago · Chicago, Illinois
- Northwestern University · Chicago, Illinois
- Northwestern Medicine Cancer Center Kishwaukee · DeKalb, Illinois
- Northwestern Medicine Cancer Center Delnor · Geneva, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify